The FDA is backing away from longstanding safeguards designed to protect teenagers from nicotine and ultraviolet exposure, decisions that have alarmed public health officials and triggered internal dissent at the agency.
In May, the FDA authorized its first fruit-flavored vaping products for adults and signaled it would ease enforcement against unauthorized e-cigarette makers still awaiting full regulatory review. The same month, the agency scrapped a decade-old proposal to ban minors from using tanning beds, citing a need to "reassess" the rule despite decades of research linking UV exposure in youth to melanoma risk.
The shifts represent a dramatic departure from the FDA's regulatory posture under previous leadership. Former FDA Commissioner Marty Makary had resisted approving flavored vapes before reversing course following pressure from the White House, according to reports. His resistance to the decision reportedly contributed to his departure from the agency.
The reversal was significant enough that Rich Danker, the chief spokesperson for Health Secretary Robert F. Kennedy Jr., resigned in protest. In a letter obtained by the New York Times, Danker objected to the FDA's decision to authorize the fruit-flavored products.
The FDA's new enforcement guidance creates what critics describe as a loophole. The agency announced it would deprioritize enforcement against vape and nicotine pouch manufacturers whose products remain under review, citing resource constraints and a focus on "the most deceptive and dangerous products." The move effectively allows unauthorized vaping products to remain on shelves while their applications are processed, potentially confusing consumers about which products carry federal approval.
Mitch Zeller, who directed the FDA's Center for Tobacco Products from 2013 to 2022, characterized the guidance as a "get-out-of-jail-free card" for companies that violated regulations by marketing products without completing the agency's scientific review process. He expressed concern about potential political interference in the authorization process, though he acknowledged the approved company appeared to have implemented strong age verification safeguards.
Public health researchers warn the decisions send mixed signals to young people about product safety. Bonnie Halpern-Felsher, a Stanford University pediatrics professor who founded the REACH Lab to combat adolescent substance use, noted that FDA approval carries significant weight with teenagers. "If you tell them that the FDA had a role in approving or disapproving something, they wake up and pay attention to that," she said, adding that the current trajectory represents a retreat from protection efforts.
The tanning bed reversal similarly troubles dermatologists. Hunter Shain, a UC San Francisco dermatology professor, pointed out that no legitimate health reason exists for minors to use tanning beds, and that age-based restrictions mirror existing policy for alcohol and tobacco. A recent study linked childhood tanning bed use to a nearly threefold increase in melanoma risk.
Zeller expressed hope the changes do not signal a broader pullback from youth protections, though he acknowledged significant uncertainty about the FDA's direction. He called Makary's departure an opportunity to "restart the public health clock."
Author James Rodriguez: "These aren't minor policy tweaks,they're philosophical statements that teen health is negotiable when industry pressure mounts."
Comments